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Accumulation of advanced oxidation protein products (AOPPs) is prevalent in obesity, advanced maternal
age, diabetes mellitus, and polycystic ovary syndrome. Alterations in the regulation and signaling of
angiogenic pathways have been recognized as a link between these conditions and pre-eclampsia.
To investigate the possible impact of AOPPs on soluble Fms-like tyrosine kinase 1 (sFlt-1) expression
in trophoblasts. A trophoblast cell line (HRT-8/SVneo) was treated with various concentrations of AOPPs.
The mRNA expression of sFlt-1, vascular endothelial growth factor (VEGF), and placental growth factor
(PlGF) in trophoblasts were measured with the use of real-time polymerase chain reaction; and the
secretion of sFlt-1, VEGF, and PlGF protein from trophoblasts were detected with the use of ELISA.
Exposure of HRT-8/SVneo cells to AOPPs induced overexpression of sFlt-1 at mRNA and protein levels in a
dose dependent manner. These effects could be inhibited by apocynin, an inhibitors of NADPH oxidase.
Our data identiﬁed AOPPs as a class of important mediator in the regulation and signaling of angiogenic
pathways of trophoblasts. Accumulation of AOPPs might contributes to the pathogenesis of preeclampsia
by promoting sFlt-1 production in trophoblasts.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Pre-eclampsia is a complex multi-system obstetric syndrome
affecting about 5e10% of pregnant women and is characterized by
hypertension and signiﬁcant proteinuria at or after 20 weeks of
pregnancy [1]. Alterations in the regulation and signaling of angio-
genic pathways have been showed to contribute to the inadequate
blood supply of the placenta in patients with pre-eclampsia [2,3].
Numerous studies have shown that trophoblast cells play
important roles during placental development [4,5]. Placental tro-
phoblasts are not only structural and biochemical barriers betweenAvenue, Guangzhou 510515,
).
ript.
r Ltd. Open access under CC BY-NC-Nthe maternal and the fetal compartment during pregnancy, but also
important for its capacity to generate angiogenesis and growth
factors to promote vascularization of the placenta during its
development.
Soluble Fms-like tyrosine kinase 1 (sFlt-1, also referred to as
sVEGFR-1) is a splice variant of the vascular endothelial growth
factor (VEGF) receptor Flt-1 that lacks the transmembrane and
cytoplasmic domains [6]. It is prominently produced by placental
trophoblasts and is secreted into the maternal circulation [7]. sFlt-1
is an antagonist of VEGF and placental growth factor (PlGF) and
may promote maternal endothelial damage and restriction of
placental growth [8]. Abundant evidence suggests that increased
trophoblast release of sFlt-1 causes the development of pre-
eclampsia [9e11]. Maynard et al. [12] demonstrated hypertension,
proteinuria, and edema in pregnant rats as a result of the admin-
istration of sFlt-1, suggesting that excess circulating sFlt-1 con-
tributes to the pathogenesis of preeclampsia.
Advanced oxidation protein products (AOPPs) are a family of
oxidized, dityrosine-containing protein products generated during
excessive production of oxidants and often carried by albuminD license.
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disorders such as diabetes [13], obesity [14], metabolic syndromes
[15], and polycystic ovary syndrome [16]. Mounting evidences
suggested that these population, when in pregnancy, have a higher
risk of developing for preeclampsia. Most recently, we demon-
strated that circulatory AOPPs are higher in patients with pre-
eclampsia and associated with the severity of the disease [17].
Given its strong involvement in the pathogenesis of pre-
eclampsia, attempts to identify factors that regulate sFlt-1 expres-
sion in trophoblasts have been made with the aim to investigate
possible novel strategies formanaging this condition. In the present
study, we hypothesis that AOPPs may enhances sFlt-1 expression in
trophoblasts and contributes to the pathogenesis of pre-eclampsia.
The aim of the present study was to determine the effect of AOPPs
on the expression of sFlt-1, VEGF and PIGF in trophoblasts.
2. Materials and methods
The Institutional Review Board at the Nanfang Hospital, Southern Medical
University approved the study protocol and all procedures.
2.1. Cell culture
First trimester extravillous trophoblast cell line (HTR-8/SVneo cells) was a kind
gift from Dr Charles H. Graham (Queen’s University, Ontario, Canada). The cells were
cultured in RPMI-1640 (HyClone, South Logan, USA) supplemented with 10% fetal
bovine serum (FBS), 100 U/ml penicillin, and 100 mg/ml streptomycin (HyClone), at
37 C plus continuous supplement of 5% CO2. Before experiments, HTR-8/SVneo cells
were cultured in RPMI-1640 supplemented with 2.5% FBS for 18e24 h.
2.2. AOPPs preparation
AOPPsehuman serum albumin (HSA) was prepared as described previously
[18,19]. Brieﬂy, HSA (100mg/ml, Sigma, St. Louis, MO) was exposed to 200mmol/L of
HOCl (Fluke, Buchs, Switzerland) for 30 min and dialyzed overnight against PBS to
remove free HOCl. The ratio of HSA to HOCL has been tested previously and the
optimal ratio (HSA to HOCL ¼ 1:134) was selected. The AOPPs preparation was
passed through a Detoxi-Gel column (Pierce, Rockford, IL, USA) to remove any
contaminated endotoxin. Endotoxin levels in the preparationwere determined with
the amebocyte lysate assay kit (Sigma) and were found to be below 0.025 EU/ml.
AOPPs content in the preparation was determined as described previously. The
content of AOPPs was 72.4  9.8 nmol/mg protein in prepared AOPPseHSA and
0.2  0.02 nmol/mg protein in native HSA.
2.3. Intervention with cell cultures
HTR-8/SVneo cells were rinsed with phosphate-buffered saline solution,
replenished with fresh serum-free media, and cultured for an additional 24 h. To
evaluate the effect of AOPPs, the cells were incubated with serum-free medium and
different concentrations of AOPPs-HSA (50, 100, and 200 mg/ml) and HSA (200 mg/
ml). Moreover, previous studies showed that plasma AOPPs can induce cellular
dysfunctions through NADPH-dependent mechanisms [18,20]. So in the present
study, we further observed the effect of apocynin, an inhibitors of NADPH oxidase,
on trophoblast in vitro and to explore whether apocynin may regulated the effect of
AOPPs on the expression of sFlt-1, VEGF and PIGF in trophoblasts.
2.4. RNA extraction, reverse transcription, and real-time quantitative polymerase
chain reaction
Total RNAwas extracted from HTR-8/SVneo cells with the use of an RNeasy mini
kit (Qiagen). One mg total RNA was reverse transcribed in a 20 ml volume with the
use of Rever Tra Ace a (Toyobo) according to the manufacturer’s instructions. Real-
time quantitative polymerase chain reaction (PCR) and data analysis were per-
formed using Lightcycler (Roche Diagnostic) according to the manufacturer’s in-
structions. 2 mL cDNA in 20 mL volumewas ampliﬁed with the use of oligonucleotide
primers based on human sFlt-1, VEGF, and PlGF sequence. sFlt-1Primers (sense 50-
GCACCTTGGTTGTGGCTGACT-30 , antisense 50-GGGCCCGGGGGTCTCATTATT-30) were
used to amplify a 643-bp product; VEGF primers (sense 50-CCCTGATGAGATCGAG-
TACATCT-30 , antisense, 50-GCCTCGGCTTGTCACATTTT-30) were used to amplify a 245-
bp product; PlGF primers (sense 50-GGGGAAGAGGAGGAGAGAGA-30 , anti-sense 50-
CTCTCACGTTGTTGAAGGCA-30) were used to amplify a product of 268 bp. The PCR
conditions for each mRNAwere as follows. sFlt-1:45 cycles at 95 C for 10 s, 63 C for
10 s, and 72 C for 27 s; VEGF:45 cycles at 95 C for 10 s, 65 C for 10 s, and 72 C for
12 s; PlGF: 40 cycles at 95 C for 10 s and 64 C for 10 s. All PCRs were followed with
melting curve analysis. Human glycerinaldehyde dehydrogenase (GAPDH) primers(Toyobo) were used to ensure RNA quality and amounts. The PCR conditions for
GAPDH were 30 cycles at 98 C for 10 s, 60 C for 2 s, and 72 C for 20 s. The Ct value
of GAPDH is stable throughout the experiment. The expression level of each mRNA
was normalized according to GAPDH levels in each case.
2.5. Measurement of protein secretions in culture supernatants
Conditioned culture media were centrifuged and stored at 80 C until assay.
Concentrations of sFlt-1, VEGF, and PlGF in supernatants were measured with the
use of their speciﬁc ELISA kits (Quantikine; R&D Systems) according to the manu-
facturer’s instructions.
2.6. Statistical analysis
All experiments were performed 3 times or more independently and all the
values were expressed as the mean  SD. Data were analyzed using one-way
analysis of variance (ANOVA) with the application of the Dunnett’s test, the least
signiﬁcant difference test, and a three-factor ANOVA classiﬁcation. Differences were
considered as statistically signiﬁcant at P < 0.05.
3. Results
3.1. Effect of AOPPs on sFlt-1, VEGF and PlGF mRNA expression in
HTR-8/SVneo cells
As shown in Fig. 1, exposure of HTR-8/SVneo cells to AOPPs
induced signiﬁcantly overexpression of sFlt-1 and VEGF at mRNA
level in a dose dependent manner, while no signiﬁcant increases of
PIGF at mRNA level were observed (Fig. 1C).
3.2. Effect of AOPPs on sFlt-1, VEGF and PlGF secretion in HTR-8/
SVneo cells
As concentrations increased, AOPPs signiﬁcantly increased sFlt-
1 protein level (Fig. 2A). Both VEGF and PIGF protein secretion
levels were slightly higher, but not signiﬁcantly increased by AOPPs
(Fig. 2B, C).
3.3. Effect of apocynin on the expression of sFlt-1 in HTR-8/SVneo
cells treated with AOPPs
Previous studies showed that plasma AOPPs exerts its wide-
range cytotoxic effect through NADPH-dependent mechanisms
[18,20]. So we further investigated whether apocynin (100 mmol/L),
an inhibitors of NADPH oxidase, can regulate the angiogenic factors
secreted by trophoblasts treatedwith AOPPs (200 mg/ml). Both sFlt-
1 and VEGF mRNA expression and protein secretion in HTR-8/
SVneo cells treated with AOPPs could be inhibited by apocynin,
while no signiﬁcant changes of PIGF at mRNA and protein level
were observed.
4. Discussion
Normal placentation requires trophoblast invasion of maternal
spiral arteries, inwhich trophoblast replaced the arterial media and
transformed the uteroplacental circulation into a high-ﬂow, low-
resistance system [21]. Vascular remodeling occurs under the in-
ﬂuence of several angiogenic factors, including VEGF and PlGF [3,9].
Mounting evidences suggested excess circulating sFlt-1, a potent
binder and inhibitor of VEGF and PlGF, could impaired the placental
angiogenesis, is increased in women destined to develop pre-
eclampsia [3,7e9]. These ﬁndings suggest an important association
between angiogenic factors and the pathogenesis of preeclampsia.
Increased recognition of trophoblasts dysfunction as a link be-
tween obesity [22], advanced maternal age [23], diabetes mellitus
[24], polycystic ovary syndrome [25] and preeclampsia has high-
lighted the importance of determining mechanisms underlying the
pathophysiological abnormalities in these populations. Here we
Fig. 2. (A) Effects of AOPPs-HSA on sFlt-1 secretion. (B) Effects of AOPPs-HSA on VEGF
secretion. (C) Effects of AOPPs-HSA on PIGF secretion. Error bars depict SEM.
(#compared with control group, P < 0.05; *compared with control group, P < 0.01;
##compared with AOPPs-HSA (200 mg/ml) group, P < 0.05; **compared with AOPPs-
HSA (200 mg/ml) group, P < 0.01).
Fig. 1. (A) Effects of AOPPs-HSA on sFlt-1 mRNA Expression. (B) Effects of AOPPs-HSA
on VEGF mRNA Expression. (C) Effects of AOPPs-HSA on PIGF mRNA Expression. Error
bars depict SEM. (#compared with control group, P < 0.05; *compared with control
group, P < 0.01; ##compared with AOPPs-HSA (200 mg/ml) group, P < 0.05;
**compared with AOPPs-HSA (200 mg/ml) group, P < 0.01).
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obesity advanced maternal age, diabetes mellitus and polycystic
ovary syndrome, enhance sFlt-1 expression at mRNA and protein
levels in cultured trophoblasts, which may impair the placental
angiogenesis and cause the endothelial dysfunctions. While native
HSA had no effect on trophoblasts, suggesting that the observed
effects were due to the protein modiﬁcation, not a property of HSA
or other contaminations.
We have also studied the effect of AOPPs on the expression of
VEGF and PIGF in HTR-8/SVneo cells. AOPPs signiﬁcantly induced
VEGF mRNA expression. In contrast, VEGF protein secretion from
trophoblasts was not increased by AOPPs. The ELISA system we
used for measuring VEGF secretion detects active (free) VEGF, not
VEGF bound to sFlt-1. It is conceivable that increased VEGF se-
cretions, due to AOPPs, do not lead to elevated levels of free
VEGF, because concurrent increased levels of sFlt-1 reduce freeVEGF. The level of PlGF, both mRNA and protein levels, was not
changed signiﬁcantly by AOPPs. Collectively, we can conclude
that AOPPs induces both VEGF and sFlt-1 mRNA expression and
secretion, but the increase in sFlt-1 overwhelms VEGF levels
and consequently diminishes the biologic effects of VEGF in
trophoblasts.
In addition, previous studies showed that plasma AOPPs exerts
its wide-range cytotoxic effects through NADPH-dependent
mechanisms [18,20]. Here, we demonstrated apocynin, an
inhibitor of NADPH oxidase, inhibited AOPPs-induced sFlt-1
expression, which suggested NADPH oxidase activation may be
responsible for the AOPPs-induced sFlt-1 expression.
It has been demonstrated that hypoxia induces sFlt-1 expression
in trophoblasts [6] and that insufﬁcient placentation, speculated to
occur in the ﬁrst trimester, increases trophoblast sFlt-1 production,
and consequently systemic and local endothelial dysfunction,
which may cause further placental hypoxia/ischaemia and sFlt-1
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demonstrated that hypoxic conditions in the placenta can promote
oxidative stress [29]. In the present study, we have shown that
AOPPs, as a novel biomarker of oxidative stress, is another factor
that enhances sFlt-1 expression in trophoblasts. Given that obesity,
advanced maternal age, diabetes mellitus, polycystic ovary syn-
drome were common high risk factors of developing for pre-
eclampsia, excessive levels of AOPPs in the circulation and
placenta may enhance sFlt-1 expression by trophoblasts and
contribute to this ‘vicious’ cycle.
In the present study, we have only focused on trophoblasts, a
major source of sFlt-1 in implantation sites. The drawbacks of the
present study are, regarding other sources of sFlt-1, previous
studies demonstrated that ﬁrst trimester decidual cells and endo-
thelial cells could also express sFlt-1 [27,28]. Moreover, mounting
evidences suggested that AOPPs may exert its cytotoxic effects
through the receptor of advanced glycation end products (RAGE)
[18,30]. So in the future, investigation were needed to explore the
effect of AOPP on the sFlt-1 expression in the decidual cells and
endothelial cells and whether the RAGE play a role in AOPPs-
induced sFlt-1 expression.
In summary, the present study has identiﬁed AOPPs as a new
class and potentially important mediators in the regulation and
signaling of angiogenic pathways of trophoblasts. Accumulation of
AOPPs might contributes to the pathogenesis of preeclampsia by
promoting sFlt-1 production in trophoblasts, probably through
induction of NADPH oxidase-dependent pathway. These data pro-
vided new information for understanding the basis of trophoblast
dysfunction under the conditions of AOPPs accumulation, such as
obesity, advanced maternal age, diabetes mellitus and polycystic
ovary syndrome. We proposed understanding the pathobiological
effect of AOPPs on trophoblasts might be an important step toward
development of new intervention for biological dysfunctions and
pre-eclampsia in these population when in pregnancy. This also
highlights the NADPH oxidase pathway may be a potential thera-
peutic target for the prevention of pre-eclampsia in the future.
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